Hence, the treatment of mice harboring SMO-mutated SHH-activated medulloblastomas with PLX5622, an inhibitor of the colony-stimulating factor 1 receptor (CSF1R), resulted in a reduced proportion of TAMs in the tumor microenvironment, shrinkage in tumor sizes, and prolonged survival of the mice [97]. The gene discussed is SHH; the disease is medulloblastoma.